LOS ANGELES (Reuters) – The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc , Eli Lilly and Co and other makers of new migraine medicines to try and fix it.
Source:: Reuters – Business News
